Regeneron Pharmaceuticals (MIC:REGN-RM) Net Income Including Noncontrolling Interests : ₽416,531.82 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Regeneron Pharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Regeneron Pharmaceuticals's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was ₽66,814.59 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was ₽416,531.82 Mil.

Regeneron Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Regeneron Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Net Income Including Noncontrolling Interests Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

261,810.70

597,047.29

265,510.09

356,733.34

474,800.16

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial															66,063.72	129,479.92	121,491.88	98,745.44	66,814.59

Regeneron Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₽416,531.82 Mil.

Regeneron Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIC:REGN-RM) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines